MedCity Investment Hub holds its spring showcase , featuring carefully selected start-up's and university spinout’s from across the life sciences industry.

Six breakthrough companies will be presenting. Each company can demonstrate technology with a direct or indirect impact on patients, and has been through a highly competitive selection process led by the Investment Hub’s panel of specialist life sciences Angel and VC investors.

Here is a taster of the pre-screened companies who will make up our February 2023 Investment Hub cohort.

Ablatus- Solving a huge female health issue. Heavy, painful periods or open surgery and a loss of fertility? Up to 8 in 10 women before 50 suffer from uterine fibroids, a market estimated at $4.6Bn. Ablatus offers the potential for incisionless, fertility-preserving, same-day procedure using our patented DC-enhanced radiofrequency ablation technology at significantly lower costs. With only 2 FDA-approved solutions amongst competitors valued between $85m-25Bn, and existing UK and US regulatory and reimbursement pathways, Ablatus is raising £2M to offer a better, faster, and cheaper treatment option for millions of women by the end of 2024.

BFB Labs –Helping solve mental health issues for young people. Half of all mental health disorders start by the age of 14, yet 70% of young people don’t get access to timely mental health support. BFB Labs combines complex therapeutic frameworks, immersive gaming and real time data for better youth mental health in a way that is fun, accessible and scalable across diverse health care systems. Having received non-dilutive NHS investment in 2019, achieved CE mark and in just 2 years have over £1 million of contract value agreed with health and social care buyers in the UK. They are now raising £2M investment to build their capacity along with a new product (NIHR funded feasibility study completed) to further growth and to hit our next milestone of a Series A raise in 2025.

Encelo has developed an alternative method to capture cells from urine, extending shelf life of samples 6-fold. Its patent-pending Cell Catcher device is designed to be sent directly to patients, used at home and mailed back to a laboratory with live cells preserved. The MVP has been validated in 3 London hospitals in 2022. Showing increased efficiency in capturing cells, compared to centrifugation. The technology is expected to impact the field of personalised medicine in renal and cancer disease areas, as well as disrupting biobanking space. Currently raising £475k for manufacture and launch of V2 of the device with 50% already committed.

Proteotype Diagnostics have originated an entirely new platform to detect, quantify and monitor disease - including its treatment. Improving health outcomes and bringing cost efficiencies to ailing healthcare systems via early detection measuring naturally occurring analytes using a simple microplate reader assay. Having already achieved clinical proof of concept for detecting cancer, multi-cancer, early-stage cancer, autoimmune (rheumatoid arthritis) and movement disorders (Parkinson’s). Now seeking £3M to help achieve their next inflection point multi-cancer early detection.

Sirgartan Therapeutics are developing a drug that modulates glutamate for the treatment of OCD. With excellent initial results and fast onset of action in rat models gained at the University of Cambridge. This repositioned drug with newly filed patents can go directly into phase 2 studies upon completion of the pre-clinical studies. Seeking £500,000 in investment to complete the pre-clinical studies and plan the phase 2

Smart Respiratory- Helping prevent asthma attacks with AI-powered software and sensors. Proactively monitoring asthma can reduce hospitalisation by 57% - but doctors lack reliable real-time information on patients. Smart Asthma uses a modular system of patented sensors, AI-based apps and medical reporting to detect and predict worsening lung function and symptoms before exacerbations and is already deployed across the UK and internationally both as a patient self-monitoring solution and as a remote patient monitoring system for medical professionals (HCPs). Raising £2.5M for further Clinical validation, market access and NHS integration

Please note we have limited capacity and registration is only open to certified investors unfortunately registrations from anyone outside of that category will not be accepted.

Please be aware MedCity do not take responsibility for the information presented by each company and any associated investments made.

MedCity Investment Hub-Virtual Showcase Event